23-Apr-2021 | Market Research Store

Asthma attacks do not end in only wheezing, coughing, a pale, and sweaty face but are quite similar in all the patients. The researchers have recently found a major difference in people and this discovery is expected to help develop important treatments. In the journal Cell Reports, the researchers from the University of Pittsburgh have used various method such as unbiased computational and bioinformatic approaches, immunology, and molecular biology to study the asthmatic patient’s immune profiles. The complexity of the disease and its mechanism needs to be studied in detail for developing better treatments. The understanding over the immune mediators of inflammation in asthma even after being classified as clinically severe showed these patients to have a completely distinct immune profile.

There are millions across the globe who are affected by asthma every year. In the US, as per the Centers for Disease Control and Prevention, there are 25 Million Americans who have asthma. Currently, the standard treatments include inhaled immunosuppressive corticosteroids such as budesonide and beclomethasone. The researchers are trying to find clinical markers that can help identify the patients who will not be resistant to treatment. The patients who are unresponsive to corticosteroid treatment have no common approach to treat this disease.

From all the asthma cases around 10% comprises of severe asthma and it is found to take up 50% of the health care costs. Currently, the asthma therapies have improved to a great extent such that the patients can enjoy quality of life. The researchers are working toward immunizing cells present in the airways of the severe asthma patients. The researchers combined machine learning, mass cytometry, and RNA-sequencing to establish a new algorithm that will help connect disease pathogenesis associated cellular pathways to the immune cells. The study showed the lungs of patients to have different levels of T cells and at the same time an increase in the IL-4 which is inflammatory molecule expressed by the innate immune cells. The latest study helps find new targets for therapy.